Movement Alert｜BioNTech SE Rises 23.13% in Regular Trading, mRNA Cancer Vaccine Breakthrough Lifts Sector

Market Focus

Aug 19

On August 19, BioNTech SE surged 23.13% in regular trading, trading at $114.43/share, with turnover of $444 million. The rally was driven by a landmark clinical success in mRNA cancer vaccine technology that lifted the entire biotech sector.

Moderna and Merck announced that their jointly developed mRNA melanoma vaccine achieved success in a Phase 3 clinical trial, marking a historic breakthrough in cancer immunotherapy. The news triggered broad gains across biotech stocks, with Moderna soaring over 128%, Merck rising over 8%, and Novavax gaining over 6%. BioNTech, as one of the pioneering mRNA platform companies, benefited directly from the validation of mRNA technology in oncology.

BioNTech itself has multiple mRNA cancer vaccine candidates in clinical development, including BNT111 in Phase II trials for advanced melanoma and BNT122 in Phase II trials for first-line melanoma. The successful proof-of-concept from Moderna's large-scale trial significantly de-risks BioNTech's own oncology pipeline and reinforces the therapeutic potential of its mRNA platform beyond infectious diseases.

(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

1
2
3
4
5
6
7
8
9
10

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.0a0bd8dc.png","ogUrl":"https://www.etasphere.com/news/1142990016"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"1142990016\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/1142990016?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-08-19 22:17","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1142990016","market":"hk","top_or_hot":-1,"title":"Movement Alert｜BioNTech SE Rises 23.13% in Regular Trading, mRNA Cancer Vaccine Breakthrough Lifts Sector","media":"Market Focus","content":"<p><p>On August 19, BioNTech SE surged 23.13% in regular trading, trading at $114.43/share, with turnover of $444 million. The rally was driven by a landmark clinical success in mRNA cancer vaccine technology that lifted the entire biotech sector.</p><p>Moderna and Merck announced that their jointly developed mRNA melanoma vaccine achieved success in a Phase 3 clinical trial, marking a historic breakthrough in cancer immunotherapy. The news triggered broad gains across biotech stocks, with Moderna soaring over 128%, Merck rising over 8%, and Novavax gaining over 6%. BioNTech, as one of the pioneering mRNA platform companies, benefited directly from the validation of mRNA technology in oncology.</p><p>BioNTech itself has multiple mRNA cancer vaccine candidates in clinical development, including BNT111 in Phase II trials for advanced melanoma and BNT122 in Phase II trials for first-line melanoma. The successful proof-of-concept from Moderna's large-scale trial significantly de-risks BioNTech's own oncology pipeline and reinforces the therapeutic potential of its mRNA platform beyond infectious diseases.</p><p>(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)</p></p>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Movement Alert｜BioNTech SE Rises 23.13% in Regular Trading, mRNA Cancer Vaccine Breakthrough Lifts Sector</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nMovement Alert｜BioNTech SE Rises 23.13% in Regular Trading, mRNA Cancer Vaccine Breakthrough Lifts Sector\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1054767329\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/51943b2858f75e05ca2ebb144b4e626a);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Market Focus </p>\n<p class=\"h-time\">2026-08-19 22:17</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p><p>On August 19, BioNTech SE surged 23.13% in regular trading, trading at $114.43/share, with turnover of $444 million. The rally was driven by a landmark clinical success in mRNA cancer vaccine technology that lifted the entire biotech sector.</p><p>Moderna and Merck announced that their jointly developed mRNA melanoma vaccine achieved success in a Phase 3 clinical trial, marking a historic breakthrough in cancer immunotherapy. The news triggered broad gains across biotech stocks, with Moderna soaring over 128%, Merck rising over 8%, and Novavax gaining over 6%. BioNTech, as one of the pioneering mRNA platform companies, benefited directly from the validation of mRNA technology in oncology.</p><p>BioNTech itself has multiple mRNA cancer vaccine candidates in clinical development, including BNT111 in Phase II trials for advanced melanoma and BNT122 in Phase II trials for first-line melanoma. The successful proof-of-concept from Moderna's large-scale trial significantly de-risks BioNTech's own oncology pipeline and reinforces the therapeutic potential of its mRNA platform beyond infectious diseases.</p><p>(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)</p></p>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BNTX","symbol_name":"BioNTech SE","start_time":0,"source_url":"","article_id":"1142990016","we_media_id":"1054767329","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1142990016","pubTimestamp":1787149053,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Market Focus","introduction":"Track stock‘s movements and relevant news","home_visible":1,"id":"1054767329","head_image":"https://static.tigerbbs.com/51943b2858f75e05ca2ebb144b4e626a"},"summary":"On August 19, BioNTech SE surged 23.13% in regular trading, trading at $114.43/share, with turnover of $444 million. The rally was driven by a landmark clinical success in mRNA cancer vaccine...","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"BNTX":"BioNTech SE"},"translate_title":"走势警报|BioNTech SE 常规交易上涨 23.13%，mRNA 癌症疫苗突破提振板块","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"BNTX":1},"content_text":"On August 19, BioNTech SE surged 23.13% in regular trading, trading at $114.43/share, with turnover of $444 million. The rally was driven by a landmark clinical success in mRNA cancer vaccine technology that lifted the entire biotech sector.Moderna and Merck announced that their jointly developed mRNA melanoma vaccine achieved success in a Phase 3 clinical trial, marking a historic breakthrough in cancer immunotherapy. The news triggered broad gains across biotech stocks, with Moderna soaring over 128%, Merck rising over 8%, and Novavax gaining over 6%. BioNTech, as one of the pioneering mRNA platform companies, benefited directly from the validation of mRNA technology in oncology.BioNTech itself has multiple mRNA cancer vaccine candidates in clinical development, including BNT111 in Phase II trials for advanced melanoma and BNT122 in Phase II trials for first-line melanoma. The successful proof-of-concept from Moderna's large-scale trial significantly de-risks BioNTech's own oncology pipeline and reinforces the therapeutic potential of its mRNA platform beyond infectious diseases.(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":true,"editions":null,"column":"","sentiment":"2","news_tag":"","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":0,"need_auth":false,"need_login_tip":false,"code":"91000000","status":"200"}}}